Aspirin for Women: Yes or No?
Study Renews Controversy, Shows Fewer Deaths in Women on Aspirin
March 26, 2007 - Last year, researchers told women that regular aspirin
won't prevent heart disease or cancer. Now a new study says it does -- for some
women, at least.
The new findings come from the Nurses' Health Study, a 30-year-long study of
nearly 80,000 women. The study suggests that women who regularly take low-dose
aspirin (81 milligrams of baby aspirin) or moderate-dose aspirin (325
milligrams of adult aspirin) are less likely to die than those who don't take
The study shows that women who took low- or moderate-dose aspirin were:
- 25% less likely to die of any cause
- 38% less likely to die of heart disease or stroke
- 28% less likely to die of colon cancer
Women who regularly took high-dose aspirin -- more than 14 adult-strength
tablets a week -- did not get a health benefit. Instead, they were 43% more
likely to die from hemorrhagic stroke compared with those who never took
aspirin. Hemorrhagic stroke is stroke due to bleeding in the brain.
Women got a heart benefit from aspirin after about five years of use. The
cancer benefit didn't appear before 10 years of regular aspirin use.
Older women and women with pre-existing risk factors for heart disease got
the largest benefit from regular low- or moderate-dose aspirin.
Andrew T. Chan, MD, MPH, assistant professor of medicine at Harvard Medical
School, and colleagues report the findings in the March 26 issue of Archives
of Internal Medicine.
"There are suggestions here that there is a subgroup of women for whom
regular aspirin makes sense," Chan tells WebMD. "But no one should take
aspirin therapy on her own. This still requires a thorough discussion of
individual risks and benefits with a doctor."
No Aspirin for Women
The evidence remains strong that daily low-dose aspirin cuts a man's risk of
heart disease and stroke -- although the drug does increase a man's risk of
ulcers and gastrointestinal bleeding.
But the new study by Chan and colleagues isn't as convincing as last year's
report from the huge Women's Health Study, suggests an editorial accompanying
the Chan report.
Why? Editorialist John A. Baron, MD, of Dartmouth Medical School, notes that
while the Chan study enrolled a large number of women for a very long time, it
is what researchers call an observational study. That means the study
researchers didn't make any changes to what the women were doing. They just
kept track of what happened to them over time.
But the Women's Health study was a clinical trial that actually looked at
what happens to women given regular aspirin compared with women not given
aspirin. The results of this trial agree with most other clinical trials of
aspirin for women.
"These new findings by Chan et al. cannot overcome the accumulated
evidence that aspirin is not particularly effective for the primary prevention
of death from cardiovascular disease in women," Baron and colleagues